Survodutide
Emerging dual-agonist for liver and weight
Weight Losssubcutaneousany
Overview
Dual GLP-1/glucagon receptor agonist in development by Boehringer Ingelheim. Shows promise for obesity and fatty liver disease.
Dosing
- Typical Dosage
- 2.4-4.8 mg
- Frequency
- Weekly
- Cycle Duration
- Ongoing
- Administration
- subcutaneous
Available Vial Sizes
10mg
Phase 3 trials ongoing. May be superior for NASH/NAFLD.
Comprehensive Information
AI-GeneratedGenerating comprehensive analysis...
This may take a moment
Mechanism of Action
Key Benefits
Optimal Timing
Potential Side Effects
Stacking Suggestions
Practical Tips
Could not load AI-generated information
Track Your Survodutide Protocol
Join UpgradeYourself to track your peptide protocols, log injections with our interactive body map, and receive AI-powered insights tailored to your health goals.
Free forever planNo credit card required100+ peptides tracked